Imbalanced estrogen metabolism in the brain: Possible relevance to the etiology of Parkinson's disease

Biomarkers

Volumn 16, Issue 5, 2011, Pages 434-444

  Gaikwad, Nilesh W ^a   Murman, Daniel ^b   Beseler, Cheryl L ^c   Zahid, Muhammad ^a   Rogan, Eleanor G ^a   Cavalieri, Ercole L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Catechol estrogen quinones; Depurinating estrogenDNA adducts; UPLC MS MS; Urinary biomarkers

Indexed keywords

CATECHOL ESTROGEN; ESTROGEN; QUINONE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONJUGATION; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; ESTROGEN METABOLISM; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; PARKINSON DISEASE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CHROMATOGRAPHY, LIQUID; DNA ADDUCTS; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 79960776421     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.588725     Document Type: Article

References (47)

1. Banger M, Hiemke C, Knuppen R, Ball P, Haupt M, Wiedemann K. (1990). Formation and metabolism of catecholestrogens in depressed patients. Biol Psychiatry 28:685-696. (Pubitemid 20333629)
2. Bisaglia M, Mammi S, Bubacco L. (2007). Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597-15605. (Pubitemid 47093273)
3. Brice A. (2005). Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128:2760-2762. (Pubitemid 41746630)
4. Cao K, Stack DE, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL. (1998). Synthesis and structure elucidation of estrogen quinones conjugated with cysteine, N-acetylcysteine, and glutathione. Chem Res Toxicol 11:909-916. (Pubitemid 28390192)
5. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. (2006). Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766:63-78. (Pubitemid 44175632)
6. Cavalieri EL, Li KM, Balu N, Saeed M, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan EG. (2002). Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23:1071-1077. (Pubitemid 34752965)
7. Cavalieri EL, Rogan EG. (2010). Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. Future Oncol 6:75-91.
8. Chinta SJ, Andersen JK. (2008). Redox imbalance in Parkinson's disease. Biochim Biophys Acta 1780:1362-1367.
9. Cookson MR, van der Brug M. (2008). Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209:5-11.
10. Dauer W, Przedborski S. (2003). Parkinson's disease: mechanisms and models. Neuron 39:889-909. (Pubitemid 37130207)
11. Deumens R, Blokland A, Prickaerts J. (2002). Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317. (Pubitemid 34634286)
12. Elswick RK Jr, Schwartz P F, Welsh JA. (1997). Interpretation of the odds ratio from logistic regression after a transformation of the covariate vector. Stat Med 16:1695-1703. (Pubitemid 27355026)
13. Gaikwad NW, Rogan EG, Cavalieri EL. (2007). Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 43:1289-1298. (Pubitemid 47429941)
14. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL. (2008). The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 122:1949-1957. (Pubitemid 351441183)
15. Gaikwad NW, Yang L, Pruthi S, Ingle JN, Sandhu N, Rogan EG, Cavalieri EL. (2009a). Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer (Auckl) 3:1-8.
16. Gaikwad NW, Yang L, Weisenburger DD, Vose J, Beseler C, Rogan EG, Cavalieri EL. (2009b). Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 14:502-512.
17. Gaikwad NW, Yang L, Rogan EG, Cavalieri EL. (2009c). Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones. Free Radic Biol Med 46:253-262.
18. Gasser T. (2005). Parkin and its role in Parkinson's disease. Parkinson's Dis 129-137.
19. Gelb DJ, Oliver E, Gilman S. (1999). Diagnostic criteria for Parkinson disease. Arch Neurol 56:33-39. (Pubitemid 29046907)
20. Gong B, Leznik E. (2007). The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 20:365-370. (Pubitemid 350219068)
21. Harada S, Fujii C, Hayashi A, Ohkoshi N. (2001). An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxifcation enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 288:887-892. (Pubitemid 33140966)
22. Hatcher JM, Pennell KD, Miller GW. (2008). Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 29:322-329.
23. Henchclife C, Beal MF. (2008). Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600-609.
24. Hnasko TS, Chuhma N, Zhang H, Goh GY, Sulzer D, Palmiter RD, Rayport S, Edwards RH. (2010). Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo. Neuron 65:643-656.
25. Huang Z, de la Fuente-Fernández R, Stoessl AJ. (2003). Etiology of Parkinson's disease. Can J Neurol Sci 30 (Suppl 1):S10-S18. (Pubitemid 36389257)
26. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608. (Pubitemid 28207717)
27. Lang AE, Lozano AM. (1998). Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053. (Pubitemid 28457867)
28. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
29. Lévay G, Ye Q, Bodell WJ. (1997). Formation of DNA adducts and oxidative base damage by copper mediated oxidation of dopamine and 6-hydroxydopamine. Exp Neurol 146:570-574. (Pubitemid 27381866)
30. Li KM, Todorovic R, Devanesan P, Higginbotham S, Köfeler H, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL. (2004). Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 25:289-297. (Pubitemid 38239812)
31. Maguire-Zeiss KA, Short DW, Federof HJ. (2005). Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Brain Res Mol Brain Res 134:18-23. (Pubitemid 40409494)
32. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. (2003). The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 4:727-738. (Pubitemid 37280152)
33. Mitamura K, Yatera M, Shimada K. (2000). Studies on neurosteroids. Part XIII. Characterization of catechol estrogens in rat brains using liquid chromatography-mass spectrometry-mass spectrometry. Analyst 125:811-814. (Pubitemid 30319121)
34. Mizuno Y, Hattori N, Kitada T, Matsumine H, Mori H, Shimura H, Kubo S, Kobayashi H, Asakawa S, Minoshima S, Shimizu N. (2001). Familial Parkinson's disease. Alpha-synuclein and parkin. Adv Neurol 86:13-21.
35. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó J F, Pérez-Tur J, Wood NW, Singleton AB. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600. (Pubitemid 39531224)
36. Parvizi N, Ellendorf F. (1983). Catecholestrogens in the brain: neuroendocrine integration. J Steroid Biochem 19:615-618.
37. Saeed M, Zahid M, Rogan E, Cavalieri E. (2005). Synthesis of the catechols of natural and synthetic estrogens by using 2-iodoxybenzoic acid (IBX) as the oxidizing agent. Steroids 70:173-178. (Pubitemid 40342610)
38. Shastry BS. (2000). Molecular etiology of Parkinson disease. Recent progress. Neuroscientist 6:234-240. (Pubitemid 30619583)
39. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL. (1996). Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 9:851-859.
40. Steece-Collier K, Maries E, Kordower JH. (2002). Etiology of Parkinson's disease: genetics and environment revisited. Proc Natl Acad Sci USA 99:13972-13974. (Pubitemid 35257609)
41. Tanner CM. (2003). Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 91:133- 142.
42. The unifed Parkinson's disease rating scale (UPDRS): status and recommendations. (2003). Mov Disord 18:738-750.
43. Yang L, Gaikwad NW, Meza J, Cavalieri EL, Muti P, Trock B, Rogan EG. (2009). Novel biomarkers for risk of prostate cancer: results from a case-control study. Prostate 69:41-48.
44. Zafar KS, Inayat-Hussain SH, Siegel D, Bao A, Shieh B, Ross D. (2006). Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 166:261-267. (Pubitemid 44416555)
45. Zahid M, Kohli E, Saeed M, Beseler C, Rogan E, Cavalieri E. (2006). The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem Res Toxicol 19:164- 172.
46. Zahid M, Saeed M, Yang L, Rogan E, Cavalieri EL. (2011). Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease. IUBMB Life, in press.
47. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeifer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607. (Pubitemid 39531225)